300 related articles for article (PubMed ID: 30925945)
1. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
Ortega H; Hahn B; Tran JN; Bell C; Shams SA; Llanos JP
Allergy Asthma Proc; 2019 May; 40(3):146-153. PubMed ID: 30925945
[No Abstract] [Full Text] [Related]
2. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.
Llanos JP; Bell CF; Packnett E; Thiel E; Irwin DE; Hahn B; Ortega H
J Asthma Allergy; 2019; 12():43-58. PubMed ID: 30774390
[TBL] [Abstract][Full Text] [Related]
3. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
5. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
7. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
[TBL] [Abstract][Full Text] [Related]
8. Insights from the trends of omalizumab and mepolizumab utilization in patients with asthma: A population-based cohort study using the National Database in Japan.
Kan-O K; Noda T; Ogata H; Masaki K; Nishioka Y; Myojin T; Adachi T; Morita H; Imamura T; Tamari M; Kainuma K;
Respir Investig; 2024 Jan; 62(1):113-120. PubMed ID: 38101278
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities.
Casale T; Molfino NA; Silver J; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):354-362.e2. PubMed ID: 34038773
[TBL] [Abstract][Full Text] [Related]
10. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
[No Abstract] [Full Text] [Related]
11. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO
Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States.
Silver J; Deb A; Packnett E; McMorrow D; Morrow C; Bogart M
J Clin Rheumatol; 2023 Dec; 29(8):381-387. PubMed ID: 37779234
[TBL] [Abstract][Full Text] [Related]
14. Impact of mepolizumab in patients with high-burden severe asthma within a managed care population.
Lugogo NL; Bogart M; Corbridge T; Packnett ER; Wu J; Hahn B
J Asthma; 2023 Apr; 60(4):811-823. PubMed ID: 35853158
[TBL] [Abstract][Full Text] [Related]
15. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
[TBL] [Abstract][Full Text] [Related]
16. Impact of Mepolizumab on Exacerbations in the US Medicare Population.
Sethi S; Bogart M; Corbridge T; Cyhaniuk A; Hahn B
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):546-554.e2. PubMed ID: 36377070
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.
Akenroye AT; Segal JB; Zhou G; Foer D; Li L; Alexander GC; Keet CA; Jackson JW
J Allergy Clin Immunol; 2023 May; 151(5):1269-1276. PubMed ID: 36740144
[TBL] [Abstract][Full Text] [Related]
18. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
Bell CF; Blauer-Peterson C; Mao J
J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
[No Abstract] [Full Text] [Related]
19. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
Yi E; Dai D; Piao OW; Zheng JZ; Park Y
J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
[TBL] [Abstract][Full Text] [Related]
20. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
